Key Takeaways:Sequential has raised $3.5 million in funding, co-led by Sparkfood and Corundum Systems Biology, to build an AI-powered skin ingredient discovery engine.Sequential is an Innovate UK– and Enterprise Singapore–backed company, with labs in Cambridge, New York City, and Singapore.With this vast genomic dataset, Sequential is innovating in areas of inflammatory disease, for example, acne, atopic dermatitis, and rosacea.Sequential, a leader in genomic testing from noninvasive human clinical samples, closed its first equity round, securing $3.5 million.WHO: Founded and led by Oliver Worsley, PhD, CEO, alongside a team of PhD-level scientists, Sequential advances innovation in skin health by quantifying how ingredients and consumer, biotech, and pharmaceutical products alter microbial and host biomarkers, using their proprietary noninvasive testing platform. Its testing platform helps to transform complex biological data into clear, actionable insights. By integrating microbial and molecular analyses, Sequential enables the development of credible, effective, and trustworthy products and claims. The company has built one of the most comprehensive clinical datasets in the industry, comprising over 50,000 samples, 4,000+ ingredients, and 10,000+ participants worldwide.By combining systems biology, clinical research infrastructure, and advanced computational modeling, Sequential aims to set a new standard for data-driven innovation in personal care and adjacent health categories.